View text source at Wikipedia

Zastaprazan

Zastaprazan
Clinical data
Trade namesJaqbo
Other namesJP-1366
Legal status
Legal status
  • Rx in South Korea
Identifiers
  • azetidin-1-yl-[8-[(2,6-dimethylphenyl)methylamino]-2,3-dimethylimidazo[1,2-a]pyridin-6-yl]methanone
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC22H26N4O
Molar mass362.477 g·mol−1
3D model (JSmol)
  • CC1=C(C(=CC=C1)C)CNC2=CC(=CN3C2=NC(=C3C)C)C(=O)N4CCC4
  • InChI=1S/C22H26N4O/c1-14-7-5-8-15(2)19(14)12-23-20-11-18(22(27)25-9-6-10-25)13-26-17(4)16(3)24-21(20)26/h5,7-8,11,13,23H,6,9-10,12H2,1-4H3
  • Key:FEQFUBYYZYQTOJ-UHFFFAOYSA-N

Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker.[1][2] In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD).[3] In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.[4]

References

[edit]
  1. ^ Yang E, Hwang I, Ji SC, Kim J, Lee S (December 2024). "Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers". CPT. 13 (12): 2150–2158. doi:10.1002/psp4.13228. PMC 11646930. PMID 39268835.
  2. ^ Tietto A, Faggin S, Scarpignato C, Savarino EV, Giron MC (September 2024). "Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease". Expert Opinion on Drug Metabolism & Toxicology: 1–16. doi:10.1080/17425255.2024.2397433. PMID 39189409.
  3. ^ Blair HA (July 2024). "Zastaprazan: First Approval". Drugs. 84 (7): 863–866. doi:10.1007/s40265-024-02057-w. PMID 38916840.
  4. ^ "Zastaprazan". AdisInsight. Springer Nature Switzerland AG.


Stub icon

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.